## Asthma Indicators for All of Ontario

|  | Asthma Indicators for All of Ontario |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Indicator | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021* | 202 |
| 1. PFT used for diagnosis (\% of incident asthma) ${ }^{+}$ | 46.84 | 47.87 | 45.84 | 45.14 | 44.91 | 44.88 | 44.96 | 43.36 | 44.02 | 45.52 | 46.88 | 48.80 | 50.02 | 50.30 | 51.62 | 50.87 | 50.86 | 51.59 | 52.85 | 54.80 | 55.83 | 55.78 | 56.83 | 54.21 | 50.97 | 55.79 | 54.4 |
| 2. PFT used for monitoring (\% of prevalent asthma) ${ }^{+}$ | 14.30 | 12.88 | 12.44 | 11.29 | 10.30 | 9.76 | 8.94 | 8.26 | 7.70 | 7.56 | 7.51 | 7.44 | 7.14 | 7.22 | 7.25 | 7.07 | 6.83 | 6.40 | 6.32 | 6.48 | 6.61 | 6.68 | 6.73 | 6.7 | 6.0 | 3.51 | 4.5 |
| 3. $\geq 1$ ICS prescription (\% of prevalent asthma) $\ddagger$ | 57.63 | 55.97 | 54.66 | 3.56 | 53.09 | 52.47 | 51.22 | 49.34 | 49.46 | 49.20 | 48.34 | 48.33 | 47.96 | 47.80 | 47.93 | 49.48 | 49.13 | 49.26 | 48.40 | 48.71 | 47.61 | 45.07 | 42.64 | 40.9 | 41.16 | 33.44 | 31.4 |
| 4. $\geq 1 \beta 2$-agonist prescription (\% of prevalent asthma) $\ddagger$ | 60.60 | 58.46 | 56.71 | 55.29 | 54.27 | 52.09 | 49.40 | 46.62 | 45.21 | 43.99 | 42.07 | 41.33 | 39.17 | 38.06 | 37.90 | 38.13 | 36.84 | 36.33 | 33.29 | 24.69 | 24.46 | 22.89 | 22.95 | 18.6 | 14.70 | 12.57 | 12.1 |
| $5 . \geq 1$ asthma ED visit (\% of prevalent asthma) | 12 | 4.36 | 3.80 | 3.51 | 3.40 | 2.98 | 83 | 2.34 | 2.24 | 2.14 | 2.07 | 1.89 | 1.6 | 1.54 | 1.4 | 1.3 | 1.1 | 1.1 | 1.0 | 1.11 | 1.0 | 0.95 | 0.97 | 0.89 | 0.85 | 0.37 | 0.5 |
| 6. $\geq 1$ asthma physician office visit (\% of prevalent asthma) | 37.28 | 33.61 | 30.78 | 29.22 | 26.98 | 25.94 | 23.28 | 21.57 | 20.73 | 19.97 | 19.25 | 18.49 | 17.04 | 16.15 | 16.05 | 14.89 | 14.00 | 13.51 | 12.99 | 13.01 | 12.5 | 12.2 | 12.3 | 11.5 | 11.8 | 9.8 | 10.2 |
| 7. $\beta 2$-agonist use (\% of prevalent asthma) $\ddagger$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0 canisters per year | 39.40 | 41.54 | 43.29 | 44.71 | 45.73 | 47.91 | 50.60 | 53.38 | 54.79 | 56.01 | 57.93 | 58.67 | 60.83 | 61.94 | 62.10 | 61.87 | 63.16 | 63.67 | 66.71 | 75.31 | 75.54 | 77.11 | 77.05 | 81.38 | 85.30 | 87.43 | 87.8 |
| 1-2 canisters per year | 18.43 | 19.02 | 18.75 | 18.90 | 19.12 | 18.95 | 18.29 | 17.60 | 17.78 | 18.39 | 17.74 | 17.92 | 17.77 | 17.56 | 17.61 | 17.89 | 17.47 | 17.81 | 16.50 | 12.23 | 12.16 | 11.27 | 11.38 | 9.6 | 7.5 | 5.8 | 5.6 |
| $\geq 3$ canisters per year | 42.17 | 39.44 | 37.95 | 36.39 | 35.15 | 33.14 | 31.12 | 29.02 | 27.43 | 25.60 | 24.33 | 23.41 | 21.40 | 20.50 | 20.28 | 20.25 | 19.37 | 18.51 | 16.79 | 12.46 | 12.30 | 11.62 | 11.57 | 8.9 | 7.15 | 6.7 | 6.5 |

## eporting period is from April 1996 to March 2023. Data for 2021 and 2022 may be incomplete due to the 2 -year algorithm to identify asthma, and numbers are subject to change.

$\mathrm{FT}=$ pulmonary function test; $\mathrm{ICS}=$ inhaled corticosteroid; $\mathrm{ED}=$ emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services us
PET data refers to individuals aged $7-99$ years in the asthma prevalent population. OHIP billings for PFT may have undercounted its utilization as it can be part of "bundled care" performed by the provider and therefore not billed to OHIP separately,
Drususe data refers to individulas $66-99$ yers with complete year ODB coverage in the asthma prevalent population.

HIP data was up to February 2024 when the tables were created.
or asthma incidence from September 2021 to March 2023, PFT data for 2.5 -year post asthma incidence are not complete as latest data were available up to February 2024 at the time when the tables were created.
Individuals with missing LHIN, rurality, or without OHIP coverage were excluded.
Index date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

## indicators - detailed description

Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date ${ }^{\text {aic }}$
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date ${ }^{\text {a.ce }}$
.
Percent of asthma prevalence aged 66 years and above with at least one prescription of $\beta 2$-agonist in one year prior to the index date $e^{\text {ce }}$
ior to the index date ${ }^{c}$
7. Distribution of the three categories of $\beta 2$-agonist use for asthma prevalence aged 66 years and above in one year prior to the index date ${ }^{\text {c,d }}$

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario

